Brasil
| Artículos de revistas
Pharmacogenetic Implications Of The Enos Polymorphisms For Cardiovascular Action Drugs
| dc.creator | Silva P.S. | |
| dc.creator | Lacchini R. | |
| dc.creator | de Aguiar Gomes V. | |
| dc.creator | Tanus-Santos J.E. | |
| dc.date | 2011 | |
| dc.date | 2015-06-30T20:25:30Z | |
| dc.date | 2015-11-26T14:49:14Z | |
| dc.date | 2015-06-30T20:25:30Z | |
| dc.date | 2015-11-26T14:49:14Z | |
| dc.date.accessioned | 2018-03-28T22:00:11Z | |
| dc.date.available | 2018-03-28T22:00:11Z | |
| dc.identifier | ||
| dc.identifier | Arquivos Brasileiros De Cardiologia. , v. 96, n. 2, p. e27 - e34, 2011. | |
| dc.identifier | 0066782X | |
| dc.identifier | 10.1590/S0066-782X2011000200017 | |
| dc.identifier | http://www.scopus.com/inward/record.url?eid=2-s2.0-79953296501&partnerID=40&md5=7632b023b43a615003de0a96f0c9fb8c | |
| dc.identifier | http://www.repositorio.unicamp.br/handle/REPOSIP/107875 | |
| dc.identifier | http://repositorio.unicamp.br/jspui/handle/REPOSIP/107875 | |
| dc.identifier | 2-s2.0-79953296501 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1253843 | |
| dc.description | The pharmacogenetics is one of the most promising fields of medicine. The conclusion of the Genome Project allowed this field to start discovering complex factors modulating the response to drugs, and new technologies are close a great expansion of the area. The cardiovascular diseases are currently among the major causes of hospitalizations and death, and have been the target of a large part of genetic studies of complex diseases. Parallel to the susceptibility to disease markers identification, it is necessary to investigate how different genetic profiles can change the responses to the currently used drugs. The biological system that controls the endothelial production of the nitric oxide has been one of the greatest targets in the pharmacological responses to the drugs used in the cardiovascular diseases therapy. This review aims at approaching the current knowledge on interaction among the genetic variations of eNOS and the pharmacological responses to the drugs used in the cardiovascular system. | |
| dc.description | 96 | |
| dc.description | 2 | |
| dc.description | e27 | |
| dc.description | e34 | |
| dc.description | Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Initial sequencing and analysis of the human genome (2001) Nature, 409 (6822), pp. 860-921 | |
| dc.description | The International HapMap Project (2003) Nature, 426 (6968), pp. 789-796 | |
| dc.description | Evans, W.E., McLeod, H.L., Pharmacogenomics--drug disposition, drug targets, and side effects (2003) N Engl J Med, 348 (6), pp. 538-549 | |
| dc.description | Gurwitz, D., McLeod, H.L., Genome-wide association studies: Powerful tools for improving drug safety and efficacy (2009) Pharmacogenomics, 10 (2), pp. 157-159 | |
| dc.description | Budnitz, D.S., Pollock, D.A., Weidenbach, K.N., Mendelsohn, A.B., Schroeder, T.J., Annest, J.L., National surveillance of emergency department visits for outpatient adverse drug events (2006) JAMA, 296 (15), pp. 1858-1866 | |
| dc.description | Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients (2004) BMJ, 329 (7456), pp. 15-19 | |
| dc.description | Peters, E.J., McLeod, H.L., Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants (2008) Pharmacogenomics, 9 (11), pp. 1573-1577 | |
| dc.description | Bader, J.S., Systems approaches for pharmacogenetics and pharmacogenomics (2008) Pharmacogenomics, 9 (3), pp. 257-262 | |
| dc.description | Topol, E.J., Frazer, K.A., The resequencing imperative (2007) Nat Genet, 39 (4), pp. 439-440 | |
| dc.description | Dorn, G.W., Cresci, S., The mechanistic imperative for pharmacogenomics (2008) Pharmacogenomics, 9 (7), pp. 801-803 | |
| dc.description | Marsh, S., Pharmacogenetics: Global clinical markers (2008) Pharmacogenomics, 9 (4), pp. 371-373 | |
| dc.description | Lacchini, R., Sabha, M., Coeli, F.B., Favero, F.F., Yugar-Toledo, J., Izidoro-Toledo, T.C., T allele of -344C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension (2009) Hypertens Res, 32 (2), pp. 159-162 | |
| dc.description | Sandrim, V.C., Palei, A.C., Cavalli, R.C., Araujo, F.M., Ramos, E.S., Duarte, G., eNOS Haplotypes associated with gestational hypertension or preeclampsia (2008) Pharmacogenomics, 9 (10), pp. 1467-1473 | |
| dc.description | Moncada, S., Higgs, A., The L-arginine-nitric oxide pathway (1993) N Engl J Med, 329 (27), pp. 2002-2012 | |
| dc.description | Kiechle, F.L., Malinski, T., Nitric oxide: Biochemistry, pathophysiology, and detection (1993) Am J Clin Pathol, 100 (5), pp. 567-575 | |
| dc.description | Cooke, J.P., Dzau, V.J., Nitric oxide synthase: Role in the genesis of vascular disease (1997) Annu Rev Med, 48, pp. 489-509 | |
| dc.description | Dudzinski, D.M., Igarashi, J., Greif, D., Michel, T., The regulation and pharmacology of endothelial nitric oxide synthase (2006) Annu Rev Pharmacol Toxicol, 46, pp. 235-276 | |
| dc.description | Perticone, F., Ceravolo, R., Pujia, A., Ventura, G., Iacopino, S., Scozzafava, A., Prognostic significance of endothelial dysfunction in hypertensive patients (2001) Circulation, 104 (2), pp. 191-196 | |
| dc.description | Sandrim, V.C., Palei, A.C., Metzger, I.F., Gomes, V.A., Cavalli, R.C., Tanus-Santos, J.E., Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia (2008) Hypertension, 52 (2), pp. 402-407 | |
| dc.description | Gomes, V.A., Casella-Filho, A., Chagas, A.C., Tanus-Santos, J.E., Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients with metabolic syndrome (2008) Nitric Oxide, 19 (4), pp. 345-350 | |
| dc.description | Gryglewski, R.J., Palmer, R.M., Moncada, S., Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor (1986) Nature, 320 (6061), pp. 454-456 | |
| dc.description | Vasquez-Vivar, J., Kalyanaraman, B., Martasek, P., Hogg, N., Masters, B.S., Karoui, H., Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors (1998) Proc Natl Acad Sci U S A, 95 (16), pp. 9220-9225 | |
| dc.description | Mason, R.P., Cockcroft, J.R., Targeting nitric oxide with drug therapy (2006) J Clin Hypertens (Greenwich), 8 (12 suppl 4), pp. 40-52 | |
| dc.description | Liao, J.K., Laufs, U., Pleiotropic effects of statins (2005) Annu Rev Pharmacol Toxicol, 45, pp. 89-118 | |
| dc.description | Palinski, W., New evidence for beneficial effects of statins unrelated to lipid lowering (2001) Arterioscler Thromb Vasc Biol, 21 (1), pp. 3-5 | |
| dc.description | Sharma, J.N., Abbas, S.A., Effect of captopril in the presence of kinin B2 receptor antagonist on duration of survival after prolonged coronary artery ligation in hypertensive rats (2006) Methods Find Exp Clin Pharmacol, 28 (4), pp. 217-221 | |
| dc.description | Cargnoni, A., Comini, L., Bernocchi, P., Bachetti, T., Ceconi, C., Curello, S., Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril (2001) Br J Pharmacol, 133 (1), pp. 145-153 | |
| dc.description | Wiemer, G., Linz, W., Hatrik, S., Scholkens, B.A., Malinski, T., Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats (1997) Hypertension, 30 (5), pp. 1183-1190 | |
| dc.description | Zhuo, J.L., Mendelsohn, F.A., Ohishi, M., Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease (2002) Hypertension, 39 (2 Pt 2), pp. 634-638 | |
| dc.description | Silvestre, J.S., Bergaya, S., Tamarat, R., Duriez, M., Boulanger, C.M., Levy, B.I., Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway (2001) Circ Res, 89 (8), pp. 678-683 | |
| dc.description | Veeravalli, K.K., Akula, A., Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction (2004) Pharmacol Res, 49 (1), pp. 23-29 | |
| dc.description | Bachetti, T., Comini, L., Pasini, E., Cargnoni, A., Curello, S., Ferrari, R., Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats (2001) J Mol Cell Cardiol, 33 (3), pp. 395-403 | |
| dc.description | Thai, H., Wollmuth, J., Goldman, S., Gaballa, M., Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor (2003) J Pharmacol Exp Ther, 307 (3), pp. 1171-1178 | |
| dc.description | Mason, R.P., Marche, P., Hintze, T.H., Novel vascular biology of third-generation L-type calcium channel antagonists: Ancillary actions of amlodipine (2003) Arterioscler Thromb Vasc Biol, 23 (12), pp. 2155-2163 | |
| dc.description | Kobayashi, N., Yanaka, H., Tojo, A., Kobayashi, K., Matsuoka, H., Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats (1999) J Cardiovasc Pharmacol, 34 (2), pp. 173-181 | |
| dc.description | Zineh, I., Pharmacogenetics of response to statins (2007) Curr Atheroscler Rep, 9 (3), pp. 187-194 | |
| dc.description | Davignon, J., Ganz, P., Role of endothelial dysfunction in atherosclerosis (2004) Circulation, 109 (23 suppl 1), pp. III27-III32 | |
| dc.description | Wolfrum, S., Jensen, K.S., Liao, J.K., Endothelium-dependent effects of statins (2003) Arterioscler Thromb Vasc Biol, 23 (5), pp. 729-736 | |
| dc.description | Laufs, U., la Fata, V., Plutzky, J., Liao, J.K., Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors (1998) Circulation, 97 (12), pp. 1129-1135 | |
| dc.description | Sumi, D., Hayashi, T., Thakur, N.K., Jayachandran, M., Asai, Y., Kano, H., A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action (2001) Atherosclerosis, 155 (2), pp. 347-357 | |
| dc.description | Jackson, G., Treatment of erectile dysfunction in patients with cardiovascular disease: Guide to drug selection (2004) Drugs, 64 (14), pp. 1533-1545 | |
| dc.description | Bivalacqua, T.J., Usta, M.F., Champion, H.C., Leungwattanakij, S., Dabisch, P.A., McNamara, D.B., Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats (2004) Int J Impot Res, 16 (1), pp. 21-29 | |
| dc.description | Nagayama, T., Zhang, M., Hsu, S., Takimoto, E., Kass, D.A., Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil (2008) J Pharmacol Exp Ther, 326 (2), pp. 380-387 | |
| dc.description | Senzaki, H., Smith, C.J., Juang, G.J., Isoda, T., Mayer, S.P., Ohler, A., Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure (2001) FASEB J, 15 (10), pp. 1718-1726 | |
| dc.description | Marsden, P.A., Heng, H.H., Scherer, S.W., Stewart, R.J., Hall, A.V., Shi, X.M., Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene (1993) J Biol Chem, 268 (23), pp. 17478-17488 | |
| dc.description | Miyahara, K., Kawamoto, T., Sase, K., Yui, Y., Toda, K., Yang, L.X., Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene (1994) Eur J Biochem, 223 (3), pp. 719-726 | |
| dc.description | Cooke, G.E., Doshi, A., Binkley, P.F., Endothelial nitric oxide synthase gene: Prospects for treatment of heart disease (2007) Pharmacogenomics, 8 (12), pp. 1723-1734 | |
| dc.description | Pereira, T.V., Rudnicki, M., Cheung, B.M., Baum, L., Yamada, Y., Oliveira, P.S., Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: Meta-analysis of 53 studies reveals evidence of publication bias (2007) J Hypertens, 25 (9), pp. 1763-1774 | |
| dc.description | Sandrim, V.C., Palei, A.C., Cavalli, R.C., Araujo, F.M., Ramos, E.S., Duarte, G., Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension (2009) Mol Hum Reprod, 15 (2), pp. 115-120 | |
| dc.description | Nakayama, M., Yasue, H., Yoshimura, M., Shimasaki, Y., Ogawa, H., Kugiyama, K., T(-786)--> C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis (2000) Am J Cardiol, 86 (6), pp. 628-634 | |
| dc.description | Miyamoto, Y., Saito, Y., Nakayama, M., Shimasaki, Y., Yoshimura, T., Yoshimura, M., Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T-->C mutation associated with coronary spastic angina (2000) Hum Mol Genet, 9 (18), pp. 2629-2637 | |
| dc.description | Nakayama, M., Yasue, H., Yoshimura, M., Shimasaki, Y., Kugiyama, K., Ogawa, H., T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm (1999) Circulation, 99 (22), pp. 2864-2870 | |
| dc.description | Wang, X.L., Mahaney, M.C., Sim, A.S., Wang, J., Wang, J., Blangero, J., Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels (1997) Arterioscler Thromb Vasc Biol, 17 (11), pp. 3147-3153 | |
| dc.description | Tsukada, T., Yokoyama, K., Arai, T., Takemoto, F., Hara, S., Yamada, A., Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans (1998) Biochem Biophys Res Commun, 245 (1), pp. 190-193 | |
| dc.description | Zhang, M.X., Zhang, C., Shen, Y.H., Wang, J., Li, X.N., Chen, L., Effect of 27nt small RNA on endothelial nitric-oxide synthase expression (2008) Mol Biol Cell, 19 (9), pp. 3997-4005 | |
| dc.description | Zhang, M.X., Zhang, C., Shen, Y.H., Wang, J., Li, X.N., Zhang, Y., Biogenesis of short intronic repeat 27-nucleotide small RNA from endothelial nitric-oxide synthase gene (2008) J Biol Chem, 283 (21), pp. 14685-14693 | |
| dc.description | Casas, J.P., Bautista, L.E., Humphries, S.E., Hingorani, A.D., Endothelial nitric oxide synthase genotype and ischemic heart disease: Meta-analysis of 26 studies involving 23028 subjects (2004) Circulation, 109 (11), pp. 1359-1365 | |
| dc.description | Tanus-Santos, J.E., Desai, M., Deak, L.R., Pezzullo, J.C., Abernethy, D.R., Flockhart, D.A., Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol (2002) Pharmacogenetics, 12 (5), pp. 407-413 | |
| dc.description | Godfrey, V., Chan, S.L., Cassidy, A., Butler, R., Choy, A., Fardon, T., The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers (2007) Cardiovasc Drug Rev, 25 (3), pp. 280-288 | |
| dc.description | Joshi, M.S., Mineo, C., Shaul, P.W., Bauer, J.A., Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: Altered caveolar localization and impaired response to shear (2007) Faseb J, 21 (11), pp. 2655-2663 | |
| dc.description | Crawford, D.C., Nickerson, D.A., Definition and clinical importance of haplotypes (2005) Annu Rev Med, 56, pp. 303-320 | |
| dc.description | Sandrim, V.C., Yugar-Toledo, J.C., Desta, Z., Flockhart, D.A., Moreno Jr., H., Tanus-Santos, J.E., Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy (2006) J Hypertens, 24 (12), pp. 2393-2397 | |
| dc.description | Metzger, I.F., Sertorio, J.T., Tanus-Santos, J.E., Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes (2007) Free Radic Biol Med, 43 (6), pp. 987-992 | |
| dc.description | Metzger, I.F., Souza-Costa, D.C., Marroni, A.S., Nagassaki, S., Desta, Z., Flockhart, D.A., Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men (2005) Pharmacogenet Genomics, 15 (8), pp. 565-570 | |
| dc.description | Abe, K., Nakayama, M., Yoshimura, M., Nakamura, S., Ito, T., Yamamuro, M., Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: A relation with the -786T>C polymorphism (2005) Pharmacogenet Genomics, 15 (5), pp. 329-336 | |
| dc.description | Nagassaki, S., Sertorio, J.T., Metzger, I.F., Bem, A.F., Rocha, J.B., Tanus-Santos, J.E., eNOS Gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite (2006) Free Radic Biol Med, 41 (7), pp. 1044-1049 | |
| dc.description | Souza-Costa, D.C., Sandrim, V.C., Lopes, L.F., Gerlach, R.F., Rego, E.M., Tanus-Santos, J.E., Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene (2007) Atherosclerosis, 193 (2), pp. 438-444 | |
| dc.description | Nagassaki, S., Herculano, R.D., Graeff, C.F., Tanus-Santos, J.E., eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity (2009) Eur J Clin Pharmacol, 65 (4), pp. 385-392 | |
| dc.description | Kunnas, T.A., Lehtimaki, T., Laaksonen, R., Ilveskoski, E., Janatuinen, T., Vesalainen, R., Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: A placebo-controlled PET study (2002) J Mol Med, 80 (12), pp. 802-807 | |
| dc.description | Turner, S.T., Chapman, A.B., Schwartz, G.L., Boerwinkle, E., Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide (2003) Am J Hypertens, 16 (10), pp. 834-839 | |
| dc.description | Liljedahl, U., Karlsson, J., Melhus, H., Kurland, L., Lindersson, M., Kahan, T., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response (2003) Pharmacogenetics, 13 (1), pp. 7-17 | |
| dc.description | Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr., J.L., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report (2003) JAMA, 289 (19), pp. 2560-2572 | |
| dc.description | Jachymova, M., Horky, K., Bultas, J., Kozich, V., Jindra, A., Peleska, J., Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy (2001) Biochem Biophys Res Commun, 284 (2), pp. 426-430 | |
| dc.description | Eisenhardt, A., Sperling, H., Hauck, E., Porst, H., Stief, C., Rubben, H., ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction (2003) Urology, 62 (1), pp. 152-157 | |
| dc.language | en | |
| dc.publisher | ||
| dc.relation | Arquivos Brasileiros de Cardiologia | |
| dc.rights | aberto | |
| dc.source | Scopus | |
| dc.title | Pharmacogenetic Implications Of The Enos Polymorphisms For Cardiovascular Action Drugs | |
| dc.type | Artículos de revistas |